Kidney drug combo under microscope: can they keep fluids in check?

NCT ID NCT05884866

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 2 study investigated how the drugs dapagliflozin and balcinrenone, alone or together, affect the body's handling of water and salts in people over 50 with stage 3 chronic kidney disease. Over 28 days, 103 participants took daily pills to measure changes in urine and blood. The goal was to understand the drugs' mechanisms, not to test a cure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
dapagliflozin and balcinrenone
What this could lead to
If successful, this study could clarify how these drugs work together to manage fluid and salt balance in chronic kidney disease, potentially improving treatment strategies.
What could go wrong
This is a small, early-phase mechanistic study with only 103 participants over 28 days. It is designed to understand how the drugs work, not to prove they are effective treatments. Results may not lead to direct patient benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE STAGE 3 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Assistance Publique-Hopitaux de Marseille (AP-HM)

    Marseille, 13005, France

  • Klinikum Nuernberg

    Nuremberg, Bavaria, 90419, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.